Royalty pharma plc RPRX 深 沪
已收盘 01-30 16:00:00 美东时间
41.68
+0.820
+2.01%
华盛通- 最 高41.72
- 今 开41.27
- 成交量 346.66万股
- 最 低 40.86
- 昨 收 40.86
- 总市值 175.47亿
- 52周最高 41.72
- 市盈率 静 21.80
- 换手率 0.82%
- 52周最低 29.00
- 委 比 -94.76%
- 总股本 4.21亿
- 历史最高 52.24
- 量 比 0.98
- 振 幅 2.10%
- 历史最低 23.17
- 每 手 1
- 风险率 2.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $50
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $48 to $50.
01-27 22:40
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
<p><p>NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced it will report its fourth quarter and full year 2025 financial results on Feb. 11, 2026, before U.S. markets open. A conference call and webcast will be held at 8:00 a.m. ET that day. Call details and webcast access are available on the company’s website. Highlights include: - Financial results release - Conference call/webcast at 8:00 a.m. ET on Feb. ...
01-20 21:15
Royalty Pharma To Reports Business Update On Jan. 13 At 44th Annual J.P. Morgan Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board, will
01-12 20:29
Royalty Pharma Raises Quarterly Dividend From $0.22 To $0.235 Per Class A Ordinary Share
Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company's
01-09 21:42
Royalty Pharma Announces Dividend Increase
Royalty Pharma announced a 6.8% increase in its quarterly dividend to $0.235 per Class A ordinary share for the first quarter of 2026, payable on March 10, 2026, to shareholders of record on February 20, 2026. The company, founded in 1996, is the largest buyer of biopharmaceutical royalties, funding innovation directly and indirectly through partnerships and acquiring existing royalties. Its portfolio includes over 35 commercial products and 19 d...
01-09 13:30
Royalty Pharma Acquires The Final Portion Of PTC Therapeutics' Remaining Royalty On Roche's Evrysdi For $240M Upfront And Up To $60M In Sales-based Milestones
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in sales-based
2025-12-30 05:43
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Royalty Pharma has acquired PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, an oral treatment for spinal muscular atrophy, has treated over 21,000 patients globally, with 2024 sales of $1.9 billion and projected to reach $2.9 billion by 2030. Royalty Pharma will now own 100% of the tiered 8% to 16% royalty, with payments increasing based on sales thresholds....
2025-12-29 21:40
Royalty Pharma Gains From FDA Approval of MYQORZO
Royalty Pharma ( ($RPRX) ) has issued an update. On December 19, 2025, Cytokine...
2025-12-23 00:58
Nuvalent’s Royalty Interest Acquired by Royalty Pharma
The latest announcement is out from Nuvalent ( ($NUVL) ). Royalty Pharma plc ha...
2025-12-16 23:28
